ESMO Asia 2022 | Optimizing genomic testing for non-colorectal GI cancers

Teresa Macarulla, MD, PhD, Vall d’Hebron University Hospital, Barcelona, ​​Spain, talks on how we can optimize genomic testing in non-colorectal GI cancers, including biliary tract, pancreatic, and esophagogastric cancers. Biliary tract cancers have a high incidence of targetable alterations, so it is important for patients to have a complete next generation sequencing (NGS) analysis as soon as possible, as targeted treatments work well. Pancreatic and esophagogastric cancers have fewer targetable alterations but promising novel targeted therapeutics are currently being investigated. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.